Your SlideShare is downloading. ×
0
Vasodilator Lecture
Vasodilator Lecture
Vasodilator Lecture
Vasodilator Lecture
Vasodilator Lecture
Vasodilator Lecture
Vasodilator Lecture
Vasodilator Lecture
Vasodilator Lecture
Vasodilator Lecture
Vasodilator Lecture
Vasodilator Lecture
Vasodilator Lecture
Vasodilator Lecture
Vasodilator Lecture
Vasodilator Lecture
Vasodilator Lecture
Vasodilator Lecture
Vasodilator Lecture
Vasodilator Lecture
Vasodilator Lecture
Vasodilator Lecture
Vasodilator Lecture
Vasodilator Lecture
Vasodilator Lecture
Vasodilator Lecture
Vasodilator Lecture
Vasodilator Lecture
Vasodilator Lecture
Vasodilator Lecture
Vasodilator Lecture
Vasodilator Lecture
Vasodilator Lecture
Vasodilator Lecture
Vasodilator Lecture
Vasodilator Lecture
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Vasodilator Lecture

3,329

Published on

Vasodilator Lecture

Vasodilator Lecture

Published in: Business, Health & Medicine
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
3,329
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
140
Comments
0
Likes
1
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide
  • Transcript

    • 1. Drugs Used In the Treatment of Congestive Heart Failure(Cont)
    • 2.  
    • 3.  BLOCKERS AT 1 BLOCKERS
    • 4. DETERMINANTS OF VENTRICULAR FUNCTION STROKE VOLUME PRELOAD CONTRACTILITY CARDIAC OUTPUT HEART RATE AFTERLOAD - Synergistic LV contraction - LV wall integrity - Valvular competence
    • 5.  
    • 6.  
    • 7.  
    • 8.  
    • 9. Venous Vasodilatation MIXED  -adrenergic Blockers ACEI Angiotensin II inhibitors K + channel activators Nitroprusside VENOUS Nitrates Molsidomine ARTERIAL Minoxidil Hydralazin VASODILATORS CLASSIFICATION Arterial Vasodilatation
    • 10. 1- VENOUS VASODILATATION Preload 2- Coronary vasodilatation Myocardial perfusion 3- Arterial vasodilatation Afterload 4- Others Pulmonary congestion Ventricular size Vent. Wall stress MVO 2 NITRATES HEMODYNAMIC EFFECTS • Cardiac output • Blood pressure
    • 11.  
    • 12.  
    • 13. Placebo Enalapril 12 11 10 9 8 7 6 5 PROBABILITY OF DEATH MONTHS 0.1 0.8 0 0.2 0.3 0.7 0.4 0.5 0.6 p< 0.001 p< 0.002 CONSENSUS N Engl J Med 1987;316:1429 ACEI SURVIVAL 4 3 2 1 0
    • 14. VASOCONSTRICTION VASODILATATION Kininogen Kallikrein Inactive Fragments Angiotensinogen Angiotensin I RENIN Kininase II Inhibitor ALDOSTERONE SYMPATHETIC VASOPRESSIN PROSTAGLANDINS tPA ANGIOTENSIN II BRADYKININ ACEI MECHANISM OF ACTION A.C.E.
    • 15. ACEI HEMODYNAMIC EFFECTS Arteriovenous Vasodilatation - PCWP and LVEDP - SVR and BP - CO and exercise tolerance No change in HR / contractility MVO 2 Renal, coronary and cerebral flow Diuresis and natriuresis
    • 16. ACEI ADVANTAGES
      • Inhibit LV remodeling post-MI
      • Modify the progression of chronic CHF
        • - Survival
        • - Hospitalizations
        • - Improve the quality of life
      • In contrast to others vasodilators, do not produce neurohormonal activation or reflex tachycardia
      • Tolerance to its effects does not develop
    • 17. ACEI UNDESIRABLE EFFECTS Inherent in their mechanism of action - Hypotension - Hyperkalemia - Angioneurotic edema Due to their chemical structure - Cutaneous eruptions - Neutropenia, thrombocytopenia - Digestive upset - Dry cough - Renal Insuff. - Dysgeusia - Proteinuria
    • 18. ANGIOTENSIN II INHIBITORS MECHANISM OF ACTION RENIN Angiotensinogen Angiotensin I ANGIOTENSIN II ACE Other paths Vasoconstriction Proliferative Action Vasodilatation Antiproliferative Action AT1 AT2 AT1 RECEPTOR BLOCKERS RECEPTORS
    • 19. AT1 RECEPTOR BLOCKERS DRUGS Losartan Valsartan Irbersartan Candesartan Competitive and selective blocking of AT1 receptors
    • 20. 0.6 PROBABILITY OF DEATH 0 Placebo (273) Prazosin (183) Hz + ISDN (186) MONTHS 0.7 0.5 0.3 0.4 0.2 0.1 VHefT-1 N Engl J Med 1986;314:1547 NITRATES SURVIVAL 0 6 12 18 24 30 36 42
    • 21.  
    • 22.  
    • 23.
      • CARDIAC GLYCOSIDES
      • SYMPATHOMIMETICS
        • Catecholamines
        • ß-adrenergic agonists
      • PHOSPHODIESTERASE INHIBITORS
        • Amrinone
        • Enoximone
      • Others
      Milrinone Piroximone POSITIVE INOTROPES
    • 24.  
    • 25.  
    • 26. Inamrine&Mirinone
    • 27. 3. Nesiritide:  natriuretic peptide a. New treatment for acute congestive heart failure and dyspnea at rest
    • 28.  
    • 29.  
    • 30.  
    • 31.  
    • 32.  
    • 33. ß-ADRENERGIC BLOCKERS INDICATIONS and UTILIZATION Not clearly established Begin with very low doses Slow augmentation of dose Slow withdrawal ?
    • 34. ß-ADRENERGIC BLOCKERS POSSIBLE BENEFICIAL EFFECTS  Density of ß 1 receptors Inhibit cardiotoxicity of catecholamines  Neurohormonal  activation  HR Antihypertensive and antianginal Antiarrhythmic Antioxidant Antiproliferative
    • 35. ALDOSTERONE Retention Na + Retention H 2 O Excretion K + Excretion Mg 2+ Collagen deposition Fibrosis - myocardium - vessels Spironolactone Edema Arrhythmias Competitive antagonist of the aldosterone receptor (myocardium, arterial walls, kidney) ALDOSTERONE INHIBITORS
    • 36.  BLOCKERS AT 1 BLOCKERS

    ×